Sign In
Buy RNA
$12.17
-0.0800 (-0.653%)
At Close: Jun 03, 2026
Atrium Therapeutics Reports First Quarter 2026 Financial Results
04:40pm, Thursday, 14'th May 2026
SAN DIEGO, May 14, 2026 /PRNewswire/ -- Atrium Therapeutics, Inc. (Nasdaq: RNA) ("Atrium," "Atrium Therapeutics" or the "Company"), a biopharmaceutical company advancing precision cardiology by deve
Atrium Therapeutics Earns $15 Million Milestone Payment from Bristol Myers Squibb Under Global Cardiovascular Collaboration
08:00am, Thursday, 23'rd Apr 2026
SAN DIEGO, April 23, 2026 /PRNewswire/ -- Atrium Therapeutics, Inc. (Nasdaq: RNA) (the "Company"), a biopharmaceutical company dedicated to delivering RNA therapeutics directly to the heart, announce
Atrium Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
10:46pm, Monday, 20'th Apr 2026
SAN DIEGO, April 20, 2026 /PRNewswire/ -- Atrium Therapeutics, Inc. (Nasdaq: RNA) (the "Company") today announced it awarded inducement grants on April 20, 2026 under the Company's 2026 Employment In
Avidity Biosciences (NASDAQ:RNA) Sets New 52-Week Low – Here’s Why
01:36am, Monday, 02'nd Mar 2026
Avidity Biosciences, Inc. (NASDAQ: RNA - Get Free Report) shares hit a new 52-week low on Saturday. The company traded as low as $13.06 and last traded at $14.75, with a volume of 7932167 shares chang
Atrium Therapeutics Launches with Approximately $270 Million to Advance Novel RNA Medicines for Rare Genetic Cardiomyopathies
09:19am, Friday, 27'th Feb 2026
Spinoff from Novartis AG's acquisition of Avidity Biosciences advances precision cardiology programs using targeted RNA delivery platform Lead candidates ATR 1072 and ATR 1086 expected to enter clinic
SAN DIEGO, Feb. 26, 2026 /PRNewswire/ -- Avidity Biosciences, Inc. ("Avidity") (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligon
Avidity Biosciences Announces Intention to Adjourn and Reconvene Special Meeting of Stockholders
08:00am, Monday, 23'rd Feb 2026
SAN DIEGO, Feb. 23, 2026 /PRNewswire/ -- Avidity Biosciences, Inc. ("Avidity") (NASDAQ: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligon
Fiera Capital Corp Has $52.39 Million Position in Avidity Biosciences, Inc. $RNA
06:20am, Friday, 20'th Feb 2026
Fiera Capital Corp lifted its position in shares of Avidity Biosciences, Inc. (NASDAQ: RNA) by 53.8% during the undefined quarter, according to its most recent filing with the Securities and Exchange
Del-desiran effectively delivered siRNA to muscle, resulting in approximately 40% mean reduction in DMPK mRNA and amelioration of missplicing Treatment demonstrated improvements in multiple measures i
Avidity Biosciences, Inc. (NASDAQ:RNA) Receives Average Recommendation of “Hold” from Brokerages
04:14am, Friday, 06'th Feb 2026
Avidity Biosciences, Inc. (NASDAQ: RNA - Get Free Report) has received a consensus recommendation of "Hold" from the twenty-one ratings firms that are presently covering the company, MarketBeat.com re
Avidity Biosciences Announces Expected Record Date for Spin-Off
09:44pm, Monday, 02'nd Feb 2026
SAN DIEGO, Feb. 2, 2026 /PRNewswire/ -- Avidity Biosciences, Inc. ("Avidity") (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonu
Harbor Small Cap Growth Fund Q4 2025 Portfolio Performance
10:30pm, Thursday, 29'th Jan 2026
From a sector perspective, strength within Industrials and Information Technology offset relative weakness in Health Care. The October earnings report reinforced confidence in Comfort Systems' ability
BOULDER, CO / ACCESS Newswire / January 28, 2026 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypoc
Avidity Biosciences (NASDAQ:RNA) Insider Sells $212,206.05 in Stock
05:38am, Monday, 26'th Jan 2026
Avidity Biosciences, Inc. (NASDAQ: RNA - Get Free Report) insider Teresa Mccarthy sold 2,929 shares of the business's stock in a transaction on Wednesday, January 21st. The shares were sold at an aver
Steven George Hughes Sells 4,895 Shares of Avidity Biosciences (NASDAQ:RNA) Stock
05:54am, Sunday, 25'th Jan 2026
Avidity Biosciences, Inc. (NASDAQ: RNA - Get Free Report) insider Steven George Hughes sold 4,895 shares of the business's stock in a transaction that occurred on Wednesday, January 21st. The shares w
